To investigate the effects of Zilongjin combined with Icotinib on the immune function and tumor angiogenesis in Lewis lung carcinoma(LLC) tumor-bearing mice.Methods:Fifty specific pathogen-free(SPF) male C57BL/6 mice were selected.Ten mice were randomly chosen to prepare LLC cell suspension，and the remaining 40 mice were subcutaneously inoculated with 0.2 mL of LLC cell suspension in the right forelimb axilla to establish the LLC tumor-bearing mouse model.The mice were then randomly divided into the model group，Zilongjin group，Icotinib group，and combination group，with 10 mice in each group.Tumor weight and tumor growth inhibition rate were compared among the groups.Enzyme-linked immunosorbent assay(ELISA) was used to detect the levels of vascular endothelial growth factor(VEGF)，interleukin-2(IL-2)，tumor necrosis factor-alpha(TNF-α)，and interferon-gamma(IFN-γ) in mouse serum，and flow cytometry was used to detect the proportion of immune cells in the spleen.Results:Compared with the Zilongjin and Icotinib groups，the combination group showed higher tumor weight and tumor growth inhibition rate in LLC tumor-bearing mice(all P<0.05)，lower levels of VEGF and microvessel density(both P<0.05)，higher proportions of CD4+T，CD8+T，and B lymphocytes(all P<0.05)，and lower levels of IL-2，TNF-α，and IFN-γ in tumor tissues(all P<0.05).Conclusion:Zilongjin combined with Icotinib has a synergistic effect，which can significantly reduce tumor weight in LLC tumor-bearing mice，inhibit angiogenesis，enhance immune function，and alleviate inflammatory reactions.